Anthony F Kreft, Iii

This inventor holds 29 USPTO granted patents, primarily in Anti-Inflammatory Compounds. Top assignees: American Home Products Corporation, Other. Active years: 1984-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anthony F Kreft, Iii. Retrieved from https://idiyas.com/inventor/anthony-f-kreft-iii

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29

% Patents Active = 96.6

Average Co-Inventor Count = 4.3

ph-index = 13

Forward Citations = 541(Granted Patents)

Location History:

Devon, PA (US) (1984 - 1988)
Trooper, PA (US) (1988 - 1992)
Langhorne, PA (US) (1991 - 2003)

Company Filing History:

28 out of 1,567

American Home Products Corporation

patents

1 out of 834,570

Other

patents

Years Active: 1984-2003

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Quinoline Derivatives

Anti-Inflammatory Agents

Sulfonamide Inhibitors

Naphthalene Compounds

Pyranoindole Inhibitors

Carbazole Inhibitors

2-Anilino Phenylacetic Acid

Leucotriene Antagonists

PLA.sub.2 Inhibitors

Oxazole Derivatives

Thiazole Naphthalenes

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6610734 - Heterocyclic sulfonamide inhibitors of beta amyloid production (2003-08-26),

2. 5830911 - Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 (1998-11-03),

3. 5824699 - Carbazole inhibitors of Cox-2 (1998-10-20),

4. 5776967 - Pyranoindole inhibitors of COX--2 (1998-07-07),

5. 5420289 - Substituted indole-, indene-, pyranoindole- and (1995-05-30),

6. 5364944 - Substituted benzoylbenzene-, biphenyl- and 2-oxazole- alkanoic acid (1994-11-15),

7. 5250693 - Quinolinylmethoxy naphthalenepropionic acid derivatives as (1993-10-05),

8. 5229516 - Substituted indole-, indene-, pyranoindole- and (1993-07-20),

9. 5218124 - Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid (1993-06-08),

10. 5208344 - Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic (1993-05-04),

11. 5159085 - 2-anilino phenylacetic acid derivatives as inhibitors of PLA.sub.2 and (1992-10-27),

12. 5103014 - Certain (1992-04-07),

13. 5084575 - Quinoline substituted naphthalenepropionic acid derivatives as (1992-01-28),

14. 5071988 - Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid (1991-12-10),

15. 5021576 - 2-Anilino phenylacetic acid derivatives (1991-06-04),

Title: Anthony F Kreft, III: A Pioneer in Pharmaceutical Innovations

Introduction: Anthony F Kreft, III, based in Langhorne, PA, has made significant contributions to the pharmaceutical industry, holding an impressive portfolio of 29 patents. His innovative work primarily focuses on the development of compounds that target critical biological mechanisms, showcasing his dedication to advancing medical science.

Latest Patents: Among his latest patents are groundbreaking inventions such as Heterocyclic sulfonamide inhibitors of beta amyloid production and Pyranoindole and tetrahydrocarbazole inhibitors of COX-2. These inventions provide novel compounds of formula I, which display the structure where R is (CH.sub.2).sub.n COOR.sup.4. Such innovations hold promising implications for the treatment of various diseases.

Career Highlights: Throughout his career, Anthony has held key positions in reputable companies, notably at American Home Products Corporation. His expertise and innovative mindset have positioned him as a crucial player in research and development within the pharmaceutical sector.

Collaborations: Anthony has collaborated with talented professionals, including John H Musser and Dennis Michael Kubrak. These partnerships have enriched his work and contributed to the successful development of novel therapeutic compounds.

Conclusion: Anthony F Kreft, III’s career is marked by a commitment to innovation and excellence in pharmaceutical research. His substantial patent portfolio not only highlights his contributions to science but also reflects his dedication to improving healthcare through innovative solutions. As he continues to develop new compounds, the medical community eagerly anticipates the impact of his work on future treatments.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]